GHRP-6 (5mg x 10), CJC-1295 no DAC (5mg x 10)

Research Overview

GHRP-6 (5mg x 10), CJC-1295 no DAC (5mg x 10) is a structured dual-pathway research peptide stack developed for laboratory investigation of growth hormone axis regulation and pituitary receptor signaling. This combination enables controlled experimental evaluation of both the growth hormone secretagogue receptor (GHS-R1a) and the growth hormone–releasing hormone (GHRH) receptor within integrated endocrine signaling models.

GHRP-6 is a synthetic hexapeptide classified as a growth hormone secretagogue that activates the GHS-R1a receptor. CJC-1295 no DAC (Mod GRF 1-29) is a modified growth hormone–releasing hormone analog designed to selectively stimulate the GHRH receptor without the drug affinity complex (DAC) extension, allowing for shorter-acting receptor interaction in research settings.

When studied together, GHRP-6 (5mg x 10), CJC-1295 no DAC (5mg x 10) allows researchers to explore complementary signaling dynamics, receptor pharmacology, and somatotropic pathway modulation under controlled in vitro conditions.

This product is supplied as lyophilized sterile powder in multi-vial format and is intended strictly for laboratory research.

Molecular Characteristics

GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide engineered to activate the GHS-R1a receptor. In laboratory research, GHRP-6 is studied for:

• Ghrelin receptor activation

• Gq protein–coupled signaling

• Phospholipase C (PLC) pathway engagement

• Inositol triphosphate (IP3) production

• Intracellular calcium mobilization

• Hypothalamic–pituitary feedback pathway modeling

GHRP-6 is one of the earliest studied secretagogues and is frequently referenced in foundational research on growth hormone axis regulation.

CJC-1295 no DAC (Mod GRF 1-29)

CJC-1295 no DAC is a modified 29–amino acid GHRH analog designed for selective activation of the GHRH receptor. Unlike DAC-bound formulations, the no DAC version is shorter-acting in laboratory systems, making it useful for investigating pulsatile receptor activation models.

In research settings, CJC-1295 no DAC is studied for:

• GHRH receptor activation

• Adenylate cyclase stimulation

• Cyclic AMP (cAMP) pathway modulation

• Protein kinase A (PKA) signaling

• Transcription factor regulation within somatotropic pathways

This receptor-specific activation complements GHS-R1a–mediated signaling initiated by GHRP-6.

Mechanism of Action (Research Context)

In controlled laboratory environments, GHRP-6 (5mg x 10), CJC-1295 no DAC (5mg x 10) allows researchers to examine dual receptor activation and signaling cross-talk.

GHRP-6 Signaling Pathway

• Binds to GHS-R1a receptor

• Activates phospholipase C (PLC)

• Produces IP3

• Mobilizes intracellular calcium

• Engages protein kinase C (PKC)

CJC-1295 no DAC Signaling Pathway

• Binds to GHRH receptor

• Activates adenylate cyclase

• Increases cyclic AMP (cAMP)

• Activates protein kinase A (PKA)

• Modulates gene transcription pathways

When used together in experimental systems, researchers can analyze:

• Complementary intracellular signaling cascades

• Signal amplification effects

• Receptor cross-talk

• Somatotropic pathway integration

• Receptor desensitization and feedback dynamics

This dual-pathway approach is commonly referenced in endocrine signaling research models.

Research Applications

GHRP-6 (5mg x 10), CJC-1295 no DAC (5mg x 10) is frequently used in laboratory studies involving:

1. Growth hormone axis modeling

2. Dual receptor activation research

3. GHS-R1a and GHRH receptor pharmacology

4. Intracellular second messenger analysis

5. Hypothalamic–pituitary regulatory pathway investigation

6. Comparative endocrine signaling studies

In molecular biology laboratories, this stack provides a structured framework for evaluating coordinated receptor activation within the somatotropic axis.

Researchers exploring endocrine receptor signaling often reference peer-reviewed scientific databases such as the National Center for Biotechnology Information (NCBI) for foundational literature on GHS and GHRH receptor mechanisms.

Stability and Laboratory Handling

Both peptides in GHRP-6 (5mg x 10), CJC-1295 no DAC (5mg x 10) are supplied in lyophilized form to preserve structural stability and reduce degradation prior to reconstitution.

For laboratory research use:

• Store under recommended refrigerated conditions

• Avoid repeated freeze–thaw cycles

• Reconstitute using sterile laboratory-grade solvent

• Follow institutional peptide handling protocols

Lyophilization enhances long-term stability and ensures consistent molecular integrity in experimental systems.

Product Specifications

GHRP-6

• Classification: Growth Hormone Releasing Peptide

• Strength: 5mg per vial

• Quantity: 10 vials

• Structure: Synthetic hexapeptide

CJC-1295 no DAC (Mod GRF 1-29)

• Classification: GHRH Analog

• Strength: 5mg per vial

• Quantity: 10 vials

• Structure: Modified 29–amino acid peptide

• Form: Lyophilized sterile powder

• Appearance: White to off-white solid

• Intended Use: Laboratory research only

Analytical Verification and Quality Standards

Each batch of GHRP-6 and CJC-1295 no DAC undergoes analytical verification to confirm peptide identity and purity. Testing methodologies may include:

• High-performance liquid chromatography (HPLC)

• Mass spectrometry analysis

• Structural sequence confirmation

• Batch-to-batch consistency validation

Lot numbers are assigned for traceability and research documentation purposes.

Broader Scientific Context

GHRP-6 (5mg x 10), CJC-1295 no DAC (5mg x 10) is widely referenced in laboratory research exploring somatotropic signaling networks and endocrine receptor cross-talk. The coordinated activation of GHS-R1a and GHRH receptors provides a structured model for analyzing complex hormonal signaling interactions within controlled experimental systems.

Compliance Notice

GHRP-6 (5mg x 10), CJC-1295 no DAC (5mg x 10) is intended strictly for laboratory research use.

This product is not approved for human consumption, therapeutic application, or clinical use. It is sold exclusively for in vitro research, analytical testing, and scientific investigation by qualified professionals.